Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HANS LEE

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1144470758
CMS profile
6525
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$61,355.42

59 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HANS LEE

NPI 1144470758 · CMS profile ID 6525

Allopathic & Osteopathic Physicians / Internal Medicine

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144470758?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HANS LEE, NPI 1144470758, CMS profile ID 6525. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144470758?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). HANS LEE, NPI 1144470758, CMS profile ID 6525. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144470758?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
HANS LEE, NPI 1144470758, CMS profile ID 6525, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1144470758?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

59 matching records · $61,355.42 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 59 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–59 of 59.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $367.5704/11/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155227528 CMS
GENZYME CORPORATION $603.7504/11/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155227530 CMS
GENZYME CORPORATION $50.0004/11/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155227532 CMS
GENZYME CORPORATION $132.3604/11/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155227534 CMS
GENZYME CORPORATION $9,764.2504/11/2024 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1155227536 CMS
Regeneron Pharmaceuticals, Inc. $1,228.0003/22/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114401613 CMS
Regeneron Pharmaceuticals, Inc. $113.7002/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114401611 CMS
Janssen Scientific Affairs, LLC $1,907.5002/14/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078860257 CMS
GlaxoSmithKline, LLC. $2,000.0002/12/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116338419 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $56,233.72 35
PY2020 $49,137.43 24
PY2021 $18,848.38 15
PY2022 $45,875.70 20
PY2023 $36,576.23 34
PY2024 $61,355.42 59
PY2025 $58,790.21 92

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $10,681.31 32
PY2025 Principal investigator $913,152.31 75
PY2024 Recipient $3,655.19 14
PY2024 Principal investigator $2,134,965.52 72
PY2023 Recipient $5,286.97 16
PY2023 Principal investigator $2,024,728.17 64
PY2022 Recipient $27,056.93 4
PY2022 Principal investigator $2,819,025.98 64
PY2021 Principal investigator $1,313,453.66 46
PY2020 Principal investigator $1,009,386.59 37
PY2019 Recipient $25,719.00 2
PY2019 Principal investigator $1,114,848.65 50

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

107 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,000.00 12/31/2025 Non-covered Recipient Entity
SCRI ONCOLOGY PARTNERS
A Phase 1b/2 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1185541390
Principal investigator 1 MENARINI SILICON BIOSYSTEMS, INC. $703.91 12/31/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616477
Principal investigator 1 MENARINI SILICON BIOSYSTEMS, INC. $3,519.55 12/31/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616660
Principal investigator 1 MENARINI SILICON BIOSYSTEMS, INC. $7,743.01 11/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616627
Principal investigator 1 Menarini Silicon Biosystems, Inc. $157.60 11/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1253059868
Recipient Regeneron Pharmaceuticals, Inc. $1,826.20 11/06/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119519
Recipient Regeneron Pharmaceuticals, Inc. $92.16 11/06/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119521
Recipient Regeneron Pharmaceuticals, Inc. $115.20 11/06/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119523
Recipient Regeneron Pharmaceuticals, Inc. $104.73 11/06/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119525
Principal investigator 1 MENARINI SILICON BIOSYSTEMS, INC. $4,927.37 10/31/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616664
Recipient Regeneron Pharmaceuticals, Inc. $366.06 10/03/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119515
Recipient Regeneron Pharmaceuticals, Inc. $256.64 10/03/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119517
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $50,873.76 10/03/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
X16097: A SAFETY STUDY OF DARATUMUMAB, IXAZOMIB, AND DEXAMETHASONE IN AL AMYLOIDOSIS No dispute reported 06/30/2026 1223273035
Principal investigator 1 MENARINI SILICON BIOSYSTEMS, INC. $5,631.28 09/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616673
Principal investigator 1 MENARINI SILICON BIOSYSTEMS, INC. $2,612.56 09/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1250415291
Recipient Regeneron Pharmaceuticals, Inc. $445.00 09/19/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119505
Recipient Regeneron Pharmaceuticals, Inc. $111.40 09/19/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119507
Recipient Regeneron Pharmaceuticals, Inc. $263.89 09/19/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119509
Recipient Regeneron Pharmaceuticals, Inc. $388.71 09/19/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119511
Recipient Regeneron Pharmaceuticals, Inc. $152.24 09/19/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119513
Principal investigator 1 MENARINI SILICON BIOSYSTEMS, INC. $3,519.55 08/31/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616655
Principal investigator 1 MENARINI SILICON BIOSYSTEMS, INC. $157.60 08/31/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1253059884
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $759.39 08/13/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184142345
Principal investigator 1 MENARINI SILICON BIOSYSTEMS, INC. $9,854.74 07/31/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616631
Principal investigator 1 Menarini Silicon Biosystems, Inc. $357.08 07/31/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616635
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $191,469.80 07/31/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1/2 STUDY OF LINVOSELTAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS No dispute reported 06/30/2026 1184142309
Recipient Regeneron Pharmaceuticals, Inc. $196.82 07/29/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119503
Recipient Regeneron Pharmaceuticals, Inc. $1,900.00 07/23/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119501
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,675.23 07/22/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184142279
Recipient Regeneron Pharmaceuticals, Inc. $340.00 07/09/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119489
Recipient Regeneron Pharmaceuticals, Inc. $146.62 07/09/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119491
Recipient Regeneron Pharmaceuticals, Inc. $121.27 07/09/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119493
Recipient Regeneron Pharmaceuticals, Inc. $74.32 07/09/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119495
Recipient Regeneron Pharmaceuticals, Inc. $310.68 07/09/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119497
Recipient Regeneron Pharmaceuticals, Inc. $46.75 07/09/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119499
Principal investigator 1 MENARINI SILICON BIOSYSTEMS, INC. $1,407.82 06/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616496
Principal investigator 1 MENARINI SILICON BIOSYSTEMS, INC. $8,446.92 06/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616685
Principal investigator 1 Menarini Silicon Biosystems, Inc. $178.54 06/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616488
Principal investigator 1 Menarini Silicon Biosystems, Inc. $357.08 06/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616703
Recipient Regeneron Pharmaceuticals, Inc. $227.11 06/14/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119487
Recipient Regeneron Pharmaceuticals, Inc. $807.25 06/07/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119485
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $238,071.41 06/05/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184142127
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25,322.05 06/05/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1/2 STUDY OF LINVOSELTAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS No dispute reported 06/30/2026 1184142139
Recipient Regeneron Pharmaceuticals, Inc. $264.32 06/02/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119483
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $53,496.00 06/02/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
CCR-MDACC-IXA-001: A PHASE 2 STUDY OF DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE, FOLLOWED BY DARATUMUMAB, IXAZOMIB, AND DEXAMETHASONE FOR RELAPSED AND/OR REFRACTORY MYELOMA No dispute reported 06/30/2026 1223273007
Recipient Regeneron Pharmaceuticals, Inc. $468.42 06/01/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119481
Principal investigator 1 MENARINI SILICON BIOSYSTEMS, INC. $703.91 05/31/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616473
Principal investigator 1 MENARINI SILICON BIOSYSTEMS, INC. $9,150.83 05/31/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616690
Principal investigator 1 Menarini Silicon Biosystems, Inc. $178.54 05/31/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616484
Principal investigator 1 Menarini Silicon Biosystems, Inc. $357.08 05/31/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616699
Principal investigator 1 Menarini Silicon Biosystems, Inc. $630.40 05/31/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1253059878
Principal investigator 1 Menarini Silicon Biosystems, Inc. $472.80 05/31/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1253059886
Recipient Regeneron Pharmaceuticals, Inc. $304.53 05/15/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119477
Recipient Regeneron Pharmaceuticals, Inc. $195.26 05/15/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119479
Principal investigator 1 MENARINI SILICON BIOSYSTEMS, INC. $2,111.73 04/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616509
Principal investigator 1 MENARINI SILICON BIOSYSTEMS, INC. $11,966.47 04/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616694
Principal investigator 1 Menarini Silicon Biosystems, Inc. $535.62 04/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616512
Principal investigator 1 Menarini Silicon Biosystems, Inc. $178.54 04/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616682
Recipient Regeneron Pharmaceuticals, Inc. $121.27 04/24/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119475
Recipient Regeneron Pharmaceuticals, Inc. $82.29 04/14/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119471
Recipient Regeneron Pharmaceuticals, Inc. $88.62 04/14/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119473
Recipient Regeneron Pharmaceuticals, Inc. $412.60 04/10/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119469
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $31,206.00 04/10/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
CCR-MDACC-IXA-001: A PHASE 2 STUDY OF DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE, FOLLOWED BY DARATUMUMAB, IXAZOMIB, AND DEXAMETHASONE FOR RELAPSED AND/OR REFRACTORY MYELOMA No dispute reported 06/30/2026 1223272981
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $31,206.00 04/10/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
CCR-MDACC-IXA-001: A PHASE 2 STUDY OF DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE, FOLLOWED BY DARATUMUMAB, IXAZOMIB, AND DEXAMETHASONE FOR RELAPSED AND/OR REFRACTORY MYELOMA No dispute reported 06/30/2026 1223272983
Recipient Regeneron Pharmaceuticals, Inc. $181.31 04/09/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119467
Principal investigator 1 Janssen Research & Development, LLC $4,413.85 04/03/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Safety Study of Daratumumab Ixazomib and Dexamethasone in Previously Treated AL Amyloidosis No dispute reported 06/30/2026 1175403681
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,600.00 04/01/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184141801
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,160.00 04/01/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184141803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,000.00 04/01/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184141805
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,460.00 04/01/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184141807
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,300.00 04/01/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184141809
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,200.00 04/01/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184141811
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,900.00 04/01/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184141813
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,300.00 04/01/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184141815
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $16,250.00 04/01/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184141817
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $32.50 04/01/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184141819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,850.00 04/01/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184141821
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18,460.00 04/01/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1/2 STUDY OF LINVOSELTAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS No dispute reported 06/30/2026 1184141831
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $16,250.00 04/01/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1/2 STUDY OF LINVOSELTAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS No dispute reported 06/30/2026 1184141833
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,900.00 04/01/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1/2 STUDY OF LINVOSELTAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS No dispute reported 06/30/2026 1184141835
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,850.00 04/01/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1/2 STUDY OF LINVOSELTAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS No dispute reported 06/30/2026 1184141837
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,293.00 04/01/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1/2 STUDY OF LINVOSELTAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC LIGHT CHAIN AMYLOIDOSIS No dispute reported 06/30/2026 1184141839
Principal investigator 1 MENARINI SILICON BIOSYSTEMS, INC. $2,111.73 03/31/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616504
Principal investigator 1 MENARINI SILICON BIOSYSTEMS, INC. $14,078.20 03/31/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616707
Principal investigator 1 Menarini Silicon Biosystems, Inc. $357.08 03/31/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616501
Principal investigator 1 Menarini Silicon Biosystems, Inc. $178.54 03/31/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616678
Principal investigator 1 Menarini Silicon Biosystems, Inc. $3.72 03/31/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1253059872
Principal investigator 1 Menarini Silicon Biosystems, Inc. $102.71 03/31/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1253059874
Principal investigator 1 Menarini Silicon Biosystems, Inc. $36.03 03/31/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1253059876
Principal investigator 1 Menarini Silicon Biosystems, Inc. $2,578.98 03/31/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1254117649
Principal investigator 1 Amgen Inc. $1,103.20 03/20/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase 1/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 Monotherapy, or in Combination With Pomalidomide, With and Without Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (ParadigMM-1B) No dispute reported 06/30/2026 1246638140
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,057.59 03/20/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184141781
Principal investigator 1 MENARINI SILICON BIOSYSTEMS, INC. $1,407.82 02/28/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616492
Principal investigator 1 MENARINI SILICON BIOSYSTEMS, INC. $16,189.93 02/28/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616646
Principal investigator 1 Menarini Silicon Biosystems, Inc. $178.54 02/28/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616481
Principal investigator 1 Menarini Silicon Biosystems, Inc. $714.16 02/28/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616650
Principal investigator 1 Menarini Silicon Biosystems, Inc. $630.40 02/28/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1253059870
Principal investigator 1 Janssen Research & Development, LLC $4,847.00 02/24/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis No dispute reported 06/30/2026 1175403515
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,151.84 02/20/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184141703
Recipient Regeneron Pharmaceuticals, Inc. $157.69 02/07/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119463
Recipient Regeneron Pharmaceuticals, Inc. $111.95 02/07/2025 Covered Recipient Physician PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1184119465
Principal investigator 1 Menarini Silicon Biosystems, Inc. $714.16 01/31/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616621
Principal investigator 1 Menarini Silicon Biosystems, Inc. $6,098.76 01/31/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616624
Principal investigator 1 Menarini Silicon Biosystems, Inc. $23,378.58 01/31/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616641
Principal investigator 1 Menarini Silicon Biosystems, Inc. $1,249.78 01/31/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1242616669
Principal investigator 1 Menarini Silicon Biosystems, Inc. $296.04 01/31/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Clearance of Circulating Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma No dispute reported 06/30/2026 1253059866
Principal investigator 1 Janssen Research & Development, LLC $8,528.00 01/27/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1175403180